Spots Global Cancer Trial Database for An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Official Title: Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
Study ID: NCT01592370
Study Description
Brief Summary: The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
Detailed Description: NOTE: Currently, this study is only open to nivolumab+daratumumab vs daratumumab monotherapy in multiple myeloma patients.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution - 0035, Clovis, California, United States
Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States
Local Institution - 0012, Los Angeles, California, United States
Local Institution - 0017, Aurora, Colorado, United States
Yale University School Of Medicine, New Haven, Connecticut, United States
Local Institution - 0023, Orlando, Florida, United States
Local Institution - 0037, Skokie, Illinois, United States
Local Institution - 0019, Indianapolis, Indiana, United States
Local Institution - 0018, Westwood, Kansas, United States
Local Institution - 0003, Baltimore, Maryland, United States
The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Local Institution - 0009, Boston, Massachusetts, United States
Local Institution - 0015, Boston, Massachusetts, United States
Local Institution - 0011, Ann Arbor, Michigan, United States
University Of Michigan Health System, Ann Arbor, Michigan, United States
Local Institution - 0002, Rochester, Minnesota, United States
Mayo Clinic, Rochester, Minnesota, United States
Local Institution - 0033, Omaha, Nebraska, United States
John Theurer Cancer Center, Hackensack, New Jersey, United States
Local Institution - 0014, Hackensack, New Jersey, United States
Local Institution - 0001, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Local Institution - 0028, Columbus, Ohio, United States
Local Institution - 0006, Portland, Oregon, United States
OHSU Center for Hematologic Malignancies, Portland, Oregon, United States
Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Local Institution - 0007, Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Local Institution - 0004, Philadelphia, Pennsylvania, United States
Huntsman Cancer Institute At The Univ. Of Utah, Salt Lake City, Utah, United States
Local Institution - 0005, Salt Lake City, Utah, United States
Local Institution - 0045, Gent, , Belgium
Local Institution - 0047, Sint-Niklaas, , Belgium
Local Institution, Yvoir, , Belgium
Local Institution - 0043, Poitiers, Vienne, France
Local Institution - 0044, Nantes Cedex 1, , France
Local Institution - 0039, Athens, , Greece
Local Institution, Bologna, , Italy
Local Institution, Chorzow, , Poland
Local Institution - 0040, Poznan, , Poland
Local Institution - 0049, Warszawa, , Poland
Local Institution - 0042, Wroclaw, , Poland
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
